BioDelivery Sciences International (BDSI) : Engaged Capital added new position in BioDelivery Sciences International during the most recent quarter end. The investment management firm now holds 1,876,550 shares of BioDelivery Sciences International which is valued at $5,291,871 , the company said in a statement filed on Aug 15, 2016 with the SEC.BioDelivery Sciences International makes up approximately 1.50% of Engaged Capital’s portfolio.
Other Hedge Funds, Including , Geode Capital Management boosted its stake in BDSI in the latest quarter, The investment management firm added 4,540 additional shares and now holds a total of 304,323 shares of BioDelivery Sciences International which is valued at $858,191. Group One Trading added BDSI to its portfolio by purchasing 92,826 company shares during the most recent quarter which is valued at $261,769. BioDelivery Sciences International makes up approx 0.02% of Group One Trading’s portfolio.Janney Montgomery Scott boosted its stake in BDSI in the latest quarter, The investment management firm added 6,550 additional shares and now holds a total of 61,300 shares of BioDelivery Sciences International which is valued at $151,411.
BioDelivery Sciences International opened for trading at $2.44 and hit $2.46 on the upside on Thursday, eventually ending the session at $2.45, with a gain of 0.41% or 0.01 points. The heightened volatility saw the trading volume jump to 4,63,393 shares. Company has a market cap of $131 M.
On the company’s financial health, BioDelivery Sciences International reported $-0.31 EPS for the quarter, based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus estimate of $-0.31. The company had revenue of $5.00 million for the quarter, compared to analysts expectations of $3.42 million. The company’s revenue was up 194.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.37 EPS.
BioDelivery Sciences International Inc. is a specialty pharmaceutical company. The Company develops and commercializes either on its own or in partnerships with third parties applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology a small erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product ONSOLIS (fentanyl buccal soluble film) as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate BELBUCA utilize its BEMA technology.